Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...

Announcing a new publication for Acta Materia Medica journal. Psoriasis is a chronic inflammatory disorder for which phosphodiesterase-4 (PDE4) inhibitors have emerged as promising therapeutic agents ...

Risk for the autoimmune hair disorder was reduced by nearly 75% in patients on these treatments for psoriasis, finds a ...

A new study published in the journal of Acta Dermato Venerologica showed that menopause might have neutral to negative impact ...